North America Vaccines Market Outlook, 2028

North America Vaccines Market Outlook, 2028

The vaccine market in North America stands as a cornerstone of public health and pharmaceutical innovation, characterised by a dynamic landscape shaped by a convergence of scientific advancements, regulatory rigour, and evolving healthcare policies. Comprising the United States and Canada, this region serves as a hub for vaccine research, development, manufacturing, and distribution, driving critical strides in the prevention and control of infectious diseases. The North American vaccine market is marked by a deep commitment to immunisation programmes, which have played a pivotal role in significantly reducing the burden of vaccine-preventable illnesses. As it continues to evolve, this market exhibits a robust interplay between government initiatives, healthcare institutions, pharmaceutical companies, and the global health community, all united in the pursuit of safeguarding public health through the development and distribution of cutting-edge vaccines. North America places a strong emphasis on public health, and vaccines are considered one of the most effective tools for preventing infectious diseases. Government health agencies, such as the Centres for Disease Control and Prevention (CDC) in the United States and Health Canada, work diligently to promote vaccination as a means of protecting the population. Childhood vaccination is widely accepted and encouraged in North America. Parents and carers typically adhere to recommended vaccination schedules for their children, understanding the importance of immunisation in preventing serious illnesses. Many states and provinces in North America have laws and regulations requiring certain vaccinations for school entry. This approach helps maintain high vaccination coverage rates among school-aged children. Seasonal influenza vaccination campaigns are a common practice in North America. Healthcare providers and employers often promote flu shots to reduce the impact of influenza outbreaks in communities and workplaces. The culture in North America places a strong emphasis on vaccine safety. Regulatory agencies closely monitor the safety of vaccines, and any potential safety concerns are thoroughly investigated and communicated to the public. Healthcare professionals, public health organisations, and advocacy groups play a vital role in educating the public about vaccines and advocating for their widespread use. Educational campaigns aim to dispel myths and misinformation.

According to the research report, ""North America Vaccines Market Overview, 2028,"" published by Bonafide Research, the North America vaccine market was valued at USD 25.64 Billion in 2022. North America has a strong culture of preventive healthcare, with vaccines being a fundamental component. Routine vaccinations for children and adults are widely accepted and promoted as a means of preventing infectious diseases. Government agencies in North America, such as the Centres for Disease Control and Prevention (CDC) in the United States and Health Canada, run extensive immunisation programs. These programmes recommend and sometimes mandate vaccinations for specific populations, ensuring high coverage rates. Vaccination is considered one of the most cost-effective public health interventions. Preventing outbreaks of vaccine-preventable diseases is a top priority for public health officials and policymakers in North America. International travel is common in North America, and some countries require proof of vaccination against certain diseases for entry. This drives demand for travel vaccines and ensures compliance with international health regulations. Outbreaks of vaccine-preventable diseases can lead to increased demand for vaccines as communities and individuals seek protection. Examples include seasonal flu outbreaks and vaccine campaigns during public health emergencies. Population growth, urbanisation, and an ageing population contribute to increased demand for vaccines. Older adults, for instance, require vaccines like influenza and shingles vaccines. North American countries actively engage in global health efforts, including providing vaccines to low- and middle-income countries. This reflects a commitment to addressing global health challenges and contributes to vaccine demand.

The North American vaccine market is segmented into three major countries, including the United States, Canada, and Mexico. The United States is the leading country with the highest market share. First and foremost, the United States boasts a substantial population size, making it one of the largest consumer markets for vaccines in North America. The country's extensive healthcare infrastructure, including a vast network of healthcare providers, clinics, and hospitals, ensures that vaccines are widely distributed and administered to a large number of individuals. Furthermore, the United States has a robust pharmaceutical industry, with numerous domestic and multinational vaccine manufacturers based in the country. These companies engage in significant research and development efforts, leading to the creation of new vaccines and the expansion of vaccine portfolios. The presence of these industry leaders, coupled with a supportive regulatory environment, promotes innovation and competition within the vaccine market. The United States also plays a pivotal role in vaccine distribution and supply chain logistics for the entire North American region. Its extensive distribution networks, pharmaceutical wholesalers, and well-established healthcare systems facilitate the efficient delivery of vaccines not only domestically but also to neighbouring countries like Canada and Mexico. Government initiatives, such as the Vaccines for Children (VFC) programme and the Advisory Committee on Immunisation Practices (ACIP), work to ensure that vaccines are accessible and affordable to a broad segment of the U.S. population, including underserved communities. These programmes contribute to the high vaccination rates observed in the country. Moreover, the United States has a long history of research excellence and investment in vaccine development, with academic institutions, government agencies, and private sector entities collaborating on vaccine-related research.

Based on the technology types, which include conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines, in North America, live attenuated vaccines have the second highest market share. Live attenuated vaccines are created by weakening a virus or bacterium in the laboratory, making it less potent but still viable. When administered, these vaccines stimulate a robust immune response, mimicking a natural infection without causing severe illness. This process results in the development of a strong and enduring immune memory. In North America, the increasing recognition of the benefits of live attenuated vaccines, particularly for diseases like measles, mumps, rubella, and varicella, has driven their demand. These vaccines have demonstrated high efficacy rates, often providing lifelong immunity after one or two doses. Additionally, the convenience of a single or limited dose compared to the multiple doses required for inactivated or subunit vaccines makes live attenuated vaccines an attractive choice for both healthcare providers and patients. Moreover, ongoing research and development efforts have led to the creation of new live attenuated vaccines targeting a broader range of diseases, further expanding their market share and driving their notable CAGR in North America. The continuous advancements in biotechnology and vaccine development techniques are likely to further enhance the efficacy and safety profiles of live attenuated vaccines, solidifying their position as a leading category in the North American vaccine market.

In terms of the route of administration, it is segmented into intramuscular and subcutaneous administration, oral administration, and others. In the North American market, others like the intradermal administration, nasal administration, intravenous administration, and many more will grow at the highest CAGR rate. Firstly, intradermal administration, which involves injecting a vaccine into the skin's dermal layer, is gaining attention due to its potential benefits. It often requires smaller vaccine doses, which can be advantageous in situations where vaccine supply is limited or for vaccines that have a higher cost per dose. Additionally, this route of administration can elicit a strong immune response while minimising adverse reactions, making it a favourable choice for specific vaccines. Nasal administration is another route that is seeing growth in North America. Nasal spray vaccines have gained popularity, particularly for influenza vaccines. They offer a needle-free alternative, making them more appealing to individuals who may have a fear of needles or for use in mass vaccination campaigns. Furthermore, some nasal vaccines have demonstrated effectiveness in generating mucosal immunity, which can be critical in protecting against respiratory diseases. Intravenous administration is used for certain specialised vaccines or in unique medical situations. This route is often employed for vaccines designed to address specific conditions, such as post-exposure prophylaxis for certain diseases. The increasing demand for such vaccines, especially in healthcare settings, contributes to the growth of intravenous administration.

End users are segmented into adult and paediatric; among them, paediatrics has the highest market in North America, and paediatric immunisation schedules are well-established and comprehensive in North America. These schedules recommend a series of vaccines to be administered during infancy and childhood to protect against a range of infectious diseases. Parents and healthcare providers adhere to these schedules, ensuring high vaccine coverage among children. Infants and young children are particularly vulnerable to vaccine-preventable diseases. Their immune systems are still developing, making them more susceptible to infections. Vaccines are crucial in providing early protection against serious illnesses during these critical developmental stages. Many states and provinces in North America have laws mandating specific vaccines for school entry. Compliance with these requirements ensures that children are up-to-date on their vaccinations before starting school, further emphasising the importance of paediatric vaccination. Parents in North America are generally well-informed about the benefits of vaccines. They prioritise their children's health and are proactive in seeking vaccination services, often working in partnership with healthcare providers to ensure their children receive recommended vaccines.

Based on these types, there are the rotavirus, pneumococcal diseases, cancer, influenza, diphtheria, pertussis, and tetanus (DTP), human papilloma virus (HPV), hepatitis, shingles, meningococcal diseases, varicella (chicken pox), mumps, and others (dengue, typhoid, polio, Japanese encephalitis, rubella, herpes Zoster, Tuberculosis, and yellow fever). In North America, pneumococcal diseases have the highest market share. Pneumococcal diseases, caused by the bacterium Streptococcus pneumonia, can lead to severe and life-threatening infections such as pneumonia, meningitis, and bloodstream infections. These diseases are associated with high morbidity and mortality rates, particularly among vulnerable populations like young children and the elderly. PCVs are a crucial component of childhood immunisation schedules in North America. They are recommended for infants and young children to protect them from pneumococcal infections. High vaccine coverage rates in paediatric populations contribute to the prominence of pneumococcal vaccines in the market. Pneumococcal vaccines are also recommended for older adults, especially those over the age of 65, to prevent pneumococcal infections and their complications. The ageing population in North America drives the demand for vaccines to protect the elderly.

The types segment includes multivalent vaccines and monovalent vaccines. In North America, people prefer their vaccines to be multivalent. Multivalent vaccines combine multiple antigens from different strains or types of a pathogen into a single vaccine. This means that a single shot can provide protection against multiple diseases or strains, reducing the number of injections required. This convenience is particularly important for children, who need several vaccinations during their early years. Multivalent vaccines are designed to align with recommended immunisation schedules. They are formulated to cover a range of diseases that are commonly encountered during childhood and adulthood. This simplifies the vaccination process and ensures that individuals receive comprehensive protection. Multivalent vaccines are valuable tools for controlling and preventing infectious diseases. They contribute to higher vaccine coverage rates in the population, which in turn can lead to herd immunity and reduced disease transmission within communities. Multivalent vaccines are often used for travellers who need protection against several diseases commonly encountered in specific regions. Travel vaccines, which include a combination of antigens, provide comprehensive coverage for individuals visiting high-risk areas.

Based on the distribution channel, it includes hospital pharmacies, retail pharmacies, institutional sales, and others. In North America, hospital pharmacies have the highest market share. North America has a well-developed and extensive healthcare infrastructure, comprising a vast network of hospitals and pharmacies. These institutions are strategically located in both urban and rural areas, ensuring broad vaccine distribution coverage. Hospitals are staffed with healthcare professionals, including doctors, nurses, and pharmacists, who are trained in vaccine administration and patient care. This expertise ensures safe and effective vaccine administration. Many vaccines require specific temperature controls to maintain their potency. Hospitals and pharmacies have the necessary cold chain infrastructure, such as refrigerators and freezers, to store and handle vaccines according to recommended temperature ranges. In addition to paediatric vaccines, hospitals and pharmacies also play a critical role in administering vaccines to adults. They offer vaccines recommended for specific age groups, including influenza, shingles, and pneumococcal vaccines.

Companies Covered in this report:

Merck & Co., Inc, Bavarian Nordic, GlaxoSmithKline PLC, Bharat Biotech International Limited, CSL, Charles River Laboratories, Creative Biogene, Daiichi Sankto Company Ltd, Emergent BioSolutions Inc., Sanofi S.A, Serum Institute of India Pvt. Ltd, AstraZeneca plc, Novavax, Pfizer Inc and Takeda Pharmaceutical Company Limited and Inovio Pharmaceutical.

Considered in this report:

• Geography: North America
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:

• North America Vaccines market Outlook with its value and forecast along with its segments
• Country-wise Transformers market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country Covered in this report:

• United States of America
• Canada
• Mexico

By Technology

• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By Route of Administration

• Intramuscular and subcutaneous administration
• Oral administration
• Others

By End-User Type

• Paediatrics
• Adults

By Disease

• Pneumococcal diseases
• Cancer
• Influenza
• Rotavirus
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Shingles
• Meningococcal diseases
• Hepatitis
• Varicella (Chicken Pox)
• Mumps
• Others

By Type

• Monovalent vaccines
• Multivalent vaccines

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:

This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:

This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.


***Please Note:It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.